Q-omics provides the consensus-scored PGAM1P9 profile across patient tissues and cancer cell-line models. PGAM1P9 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, PGAM1P9 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, PGAM1P9 RNA expression shows 6,255 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CHOL, BRCA, and GBM as cancer lineages where PGAM1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGAM1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGAM1P9 survival associations across molecular data types. PGAM1P9 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGAM1P9 RNA expression–survival associations across cancer types. High PGAM1P9 expression shows unfavorable associations in CHOL, UVM, PCPG, PAAD, READ and THCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for PGAM1P9 RNA expression.
This table summarizes PGAM1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PGAM1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGAM1P9 shows higher tumor expression in BRCA, HNSC, LUAD and KIRP. The BRCA box plot shows higher PGAM1P9 RNA expression in tumor versus normal tissue (log2 FC = +0.031, t-test p = .024).
This table shows molecular features associated with PGAM1P9 in patient tissues and cancer cell lines. In patient samples, PGAM1P9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
